Real-world use of biologics for non-systemic juvenile idiopathic arthritis: Information from a Japanese hospital claims database
Modern Rheumatology · 2026
DOI: 10.1093/mr/roag025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Takashi Funatogawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Juvenile, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Limited information is available on patients with non-systemic juvenile idiopathic arthritis (nsJIA) receiving biologics in Japan. The types of biologics, treatment duration, prior and concomitant treatments, administration routes (intravenous [IV] or subcutaneous [SC] injection), and patient characteristics were investigated.
Methods
We investigated nsJIA, excluding psoriatic arthritis and ankylosing spondylitis, using data from a Japanese hospital claims database (2008–2024).
Results
Of the 4191 nsJIA patients in the database, 965 (23.0%) received one or more biologics. For the first biologic, the most common were antitumour necrosis factor (anti-TNF) drugs (55.3% overall; adalimumab SC, 32.1%; etanercept SC, 9.8%; infliximab IV, 9.2%; others, < 2.1% each), followed by anti-interleukin-6 (anti-IL-6) drugs (39.9% overall; tocilizumab, 39.1% [IV, 32.4%; SC, 6.6%]; others, ≤ 0.7%), abatacept IV or SC (3.7%), and canakinumab SC (1.0%). Of the patients receiving anti-TNF and anti-IL-6 drugs, 40% and 58% continued treatment for ≥1 year, respectively. The most common conventional synthetic disease-modifying antirheumatic drug (csDMARD) administered prior to anti-TNF and anti-IL-6 drugs was methotrexate [39.0% (anti-TNF) and 33.5% (anti-IL-6)], with others at ≤ 3.6%. The most common csDMARD used concomitantly was also methotrexate [66.9% (anti-TNF) and 50.4% (anti-IL-6)], with others < 8.6%.
Conclusions
Our study describes the real-world usage of biologics for nsJIA in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
Zitieren
APA
Funatogawa, T., Mii, K., Katayama, S., Aoki, Y., Matsubara, Y., Kojima, K., & Hoshiba, M. (2026). Real-world use of biologics for non-systemic juvenile idiopathic arthritis: Information from a Japanese hospital claims database. Modern Rheumatology. https://doi.org/10.1093/mr/roag025
Vancouver
Funatogawa T, Mii K, Katayama S, Aoki Y, Matsubara Y, Kojima K, et al. Real-world use of biologics for non-systemic juvenile idiopathic arthritis: Information from a Japanese hospital claims database. Modern Rheumatology. 2026. doi:10.1093/mr/roag025
BibTeX
@article{Funatogawa2026,
author = {Funatogawa, Takashi and Mii, Kazuma and Katayama, Saki and Aoki, Yuka and Matsubara, Yasuaki and Kojima, Kazuki and Hoshiba, Mariko},
title = {Real-world use of biologics for non-systemic juvenile idiopathic arthritis: Information from a Japanese hospital claims database},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roag025}
}
EUVIMED